sEphB4-HSA in Treating Patients with Kaposi Sarcoma

Status: Active

Description

This phase II trial studies recombinant EphB4-HSA fusion protein (sEphB4-HSA) in treating patients with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that provide blood to the cancer, and may also prevent cancer cells from growing.

Eligibility Criteria

Inclusion Criteria

  • Participants may be treatment naive, refractory to or intolerant of one or more prior therapies, or treated with prior systemic treatment including but not limited to liposomal doxorubicin
  • Participants must have biopsy-proven KS involving skin with or without visceral involvement
  • If HIV-positive, any cluster of differentiation (CD)4 count will be allowed on study
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky performance score (KPS) >= 50%
  • Life expectancy of greater than 3 months
  • Absolute neutrophil count >= 1,500/mcL* (within 21 days of enrollment) * Participants may be receiving growth factor support to meet these criteria
  • Platelets >= 100,000/mcL (within 21 days of enrollment)
  • Total bilirubin =< 1.5 x upper limit of normal (ULN) (within 21 days of enrollment)
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
  • Creatinine within normal institutional limit for the reference lab OR creatinine clearance >= 60 mL/min/1.73 m^2 as calculated by Cockcroft-Gault formula for participants with creatinine levels above institutional normal (within 21 days of enrollment)
  • Participants must have cutaneous lesion(s) amenable to four (4) 5-mm tumor biopsies during the study (either 4 separate lesions measuring >= 5 mm each OR 2 separate lesions measuring >= 10 mm each) and at least five additional lesions measurable for assessment with no improvement over the past month
  • Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to enrollment and again within 24 hours prior to starting cycle 1 of sEphB4-HSA; further, they must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME during receipt of sEphB4-HSA, and 12 weeks after discontinuation of sEphB4-HSA; FCBP must also agree to ongoing pregnancy testing; men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy * A female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
  • Documentation of HIV status; if participant is HIV positive, HIV-1 infection, as documented by any federally approved, licensed HIV rapid test performed in conjunction with screening (or enzyme-linked immunosorbent assay [ELISA] test kit, and confirmed by Western blot or other approved test, or HIV rapid multispot antibody differentiation assay); alternatively, this documentation may include a record demonstrating that another physician has documented the participant's HIV status based on either: 1) approved diagnostic tests, or 2) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and/or current management of HIV infection * If the participant is HIV negative, documentation of a negative result for any federally approved, licensed HIV rapid test within 4 weeks prior to study enrollment will suffice; if the initial rapid test is positive, further approved confirmatory test results must be present to document the subject’s HIV status
  • If participant is HIV positive, participants must be on a stable antiretroviral regimen for at least 12 weeks prior to study enrollment
  • There should be no evidence for improvement in KS in the 3 months prior to study enrollment, unless there is evidence for progression of KS in the 4 weeks immediately prior to study enrollment
  • Participants must, in the opinion of the investigator, be capable of complying with the protocol

Exclusion Criteria

  • Inability to understand and inability to provide informed consent
  • Participants who are receiving any other investigational agents
  • Participants who have had anti-neoplastic treatment for KS (including chemotherapy, radiotherapy, local treatment including topical fluorouracil [5-FU], biological therapy or investigational therapy) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study OR those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to sEphB4-HSA or other agents used in study
  • Concurrent, acute, active infection, or treatment for infection, other than oral thrush, genital herpes, or long-term (i.e. > 1 month) suppression therapy after treatment and clearance of the infection episode (examples include Coccidioides, mycobacterium avium complex) within 14 days of enrollment
  • Participants for whom front-line cytotoxic therapy is indicated (i.e. symptomatic visceral or pulmonary KS or symptomatic KS impairing functional status)
  • Concurrent neoplasia requiring cytotoxic therapy
  • Participant is =< 2 years free of another primary malignancy; exceptions include the following: * Basal cell skin cancer * Cervical carcinoma in situ * Anal carcinoma in situ
  • Any steroid treatment except for that required for replacement therapy in adrenal insufficiency, topical or injected testosterone for hypogonadism, or inhaled steroids for the treatment of asthma
  • Previous local therapy of any KS-indicator lesion unless the lesion has clearly progressed since that local treatment; any prior local treatment to indicator lesions regardless of the elapsed time should not be allowed unless there is evidence of clear-cut progression of said lesion
  • Female participants who are pregnant, lactating, or breast-feeding
  • Pregnant women are excluded from this study because sEphB4-HSA has not been tested in pregnant women and it could have potential teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sEphB4-HSA, breastfeeding should be discontinued if the mother is treated with sEphB4-HSA
  • Participants with a recent history (< 6 months) of a major infarct including but not inclusive to bowel ischemia, cerebral vascular accident, transient ischemic attack, myocardial infarction, limb ischemia, or skin necrosis
  • Participants with a QTcF (Fridericia correction formula) > 480 ms on 2 out of 3 electrocardiograms (EKGs) (if first EKG is < 480, no need to repeat, if first EKG is > 480 repeat twice for a total of 3 EKGs)
  • Participants with systolic blood pressure > 120 mm Hg or diastolic blood pressure > 80 mm Hg who are unwilling to start antihypertensives, or participants with systolic blood pressure > 140 mm Hg, or diastolic blood pressure > 90 mm Hg, with or without use of anti-hypertensive medication (participants may not enroll onto the study until blood pressure [BP] is =< 140/90 mm Hg with or without antihypertensive medication)
  • Participants with a recent history (< 6 months) of a major bleed which will be defined as a symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level 2 grams/dL or more, or leading to transfusion of two or more units of whole blood or packed red cells
  • Participants on any dose of warfarin or are on full dose anticoagulation with other agents including low molecular weight heparin, antithrombin agents, antiplatelet agents and full dose aspirin within 7 days prior to study enrollment; participants on prophylactic doses of low molecular weight heparin are allowed
  • Cardiac related illnesses including, but not limited to: * Symptomatic congestive heart failure including participants with grade III/IV cardiac disease as defined by the New York Heart Association functional criteria * Unstable angina pectoris * Cardiac arrhythmia
  • Proteinuria as defined as >= 2 positive (+) on urine dipstick; if dipstick urinalysis shows >= 2+ proteinuria, 24-hour urine for protein must be < 2 grams
  • Participants with diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months, or any other intercurrent medical condition that contraindicates treatment with sEphB4-HSA or places the participant at undue risk for treatment related complications
  • Physical or psychiatric illness/social situations that in the estimation of the investigator would limit compliance with study requirements or place the participant at high risk of toxicity or non-compliance

Locations & Contacts

California

La Jolla
UC San Diego Moores Cancer Center
Status: Active
Contact: Ida C. Wong-Sefidan
Email: cancercto@ucsd.edu
Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: Active
Contact: William Wachsman
Phone: 858-552-8585ext2628
Email: wwachsman@ucsd.edu
UCLA Center for Clinical AIDS Research and Education
Status: Active
Contact: Ida C. Wong-Sefidan
Phone: 858-822-6276
Email: icwong@ucsd.edu

Illinois

Chicago
John H Stroger Jr Hospital of Cook County
Status: Active
Contact: Paul G. Rubinstein
Phone: 312-864-7277
Email: prubinstein@cookcountyhhs.org

Missouri

Saint Louis
Barnes Jewish Hospital Foundation
Status: Active
Contact: Lee Ratner
Phone: 314-362-5677
Email: lratner@wustl.edu
Siteman Cancer Center at Washington University
Status: Active
Contact: Ida C. Wong-Sefidan
Phone: 858-822-6276
Email: icwong@ucsd.edu
Washington University School of Medicine
Status: Active
Contact: Lee Ratner
Phone: 314-362-5677
Email: lratner@wustl.edu

Washington

Seattle
Benaroya Research Institute at Virginia Mason
Status: Active
Contact: David M. Aboulafia
Phone: 206-223-6193
Email: hemdma@vmmc.org

Trial Objectives and Outline

PRIMARY OBJECTIVES:

I. To evaluate the clinical response and toxicity of recombinant EphB4-HSA fusion protein (sEphB4-HSA) (at initial dosing of 10 mg/kg every 2 weeks) in participants with Kaposi sarcoma.

SECONDARY OBJECTIVES:

I. To assess the safety of sEphB4-HSA in participants with Kaposi sarcoma (KS).

II. To determine trough level exposure of sEphB4-HSA and correlate with tumor response.

III. To characterize the pharmacodynamics of sEphB4-HSA and correlate these effects with clinical response.

IV. Effects on viral replication and gene expression of human herpes virus-8 (HHV-8).

V. Changes in vascular endothelial growth factor (VEGF)-Notch-EphrinB2 angiogenic pathway.

VI. Effects on immune response and modulation.

VII. Effects on tumor cell apoptosis and proliferation.

VIII. Effects on sEphB4-HSA on human immunodeficiency virus (HIV) plasma viral loads in participants with HIV.

IX. To archive peripheral blood mononuclear cells (PBMCs) and tissue samples to be used in conjunction with samples collected in subsequent trials of sEphB4-HSA for future studies including identification of biomarkers predictive of response.

EXPLORATORY OBJECTIVES:

I. Describe baseline quality of life (QOL) scores, using the functional assessment of HIV Infection (FAHI) + Kaposi sarcoma (KS) questionnaire, in participants with KS, and explore changes in QOL of participants on treatment with sEphB4-HSA.

OUTLINE:

Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 1 hour on days 1 and 15. Treatment repeats every 28 days for up to 12 courses in the absence of further disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 1 month; patients with partial response or better are followed up every 3 months for up to 1 year.

Trial Phase & Type

Trial Phase

Phase II

Trial Type

Treatment

Lead Organization

Lead Organization
AIDS Malignancy Consortium

Principal Investigator
Ida C. Wong-Sefidan

Trial IDs

Primary ID AMC-096
Secondary IDs NCI-2015-00052, 096, AMC 096
Clinicaltrials.gov ID NCT02799485